Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Overview of attention for article published in Lancet Oncology, February 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 6 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 27 X users

patent: 87 patents
facebook: 5 Facebook pages
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 882 Mendeley

So far, Altmetric has seen 3 posts from 3 blogs.

The Complexity of PD-L1 Biology

Cofactor Genomics, 14 Nov 2019

By Kevin Flanagan…

The Significance of PD-L1 Expression in Non-Small Cell Lung Cancer

Online First/Online Only: Posts, 11 Mar 2016

BY AARON MANSFIELD, MDImmunotherapy is rapidly changing the treatment landscape for non-small cell lung cancer (NSCLC). Two…

FDA Approves First Immunotherapy Treatment for Lung Cancer

Cancer Currents: An NCI Cancer Research Blog, 24 Mar 2015

The FDA has approved nivolumab to treat patients with advanced non-small cell lung cancer that has progressed during or after…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.